Results 11 to 20 of about 2,739,450 (298)

Clinical proteomic analysis of scrub typhus infection

open access: yesClinical Proteomics, 2018
Background Scrub typhus is an acute and febrile infectious disease caused by the Gram-negative α-proteobacterium Orientia tsutsugamushi from the family Rickettsiaceae that is widely distributed in Northern, Southern and Eastern Asia. In the present study,
Edmond Changkyun Park   +9 more
doaj   +1 more source

Antibiotic treatment modulates protein components of cytotoxic outer membrane vesicles of multidrug-resistant clinical strain, Acinetobacter baumannii DU202

open access: yesClinical Proteomics, 2018
Background Outer membrane vesicles (OMVs) of Acinetobacter baumannii are cytotoxic and elicit a potent innate immune response. OMVs were first identified in A. baumannii DU202, an extensively drug-resistant clinical strain.
Sung Ho Yun   +11 more
doaj   +1 more source

Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. [PDF]

open access: yes, 2012
BackgroundWe previously developed a bladder cancer-specific ligand (PLZ4) that can specifically bind to both human and dog bladder cancer cells in vitro and in vivo. We have also developed a micelle nanocarrier drug-delivery system.
de Vere White, Ralph   +8 more
core   +2 more sources

Ag nanocomposite hydrogels with immune and regenerative microenvironment regulation promote scarless healing of infected wounds

open access: yesJournal of Nanobiotechnology, 2023
Background Bacterial infection, complex wound microenvironment and persistent inflammation cause delayed wound healing and scar formation, thereby disrupting the normal function and appearance of skin tissue, which is one of the most problematic clinical
Yihui Zhang   +6 more
doaj   +1 more source

Patient-centric trials for therapeutic development in precision oncology [PDF]

open access: yes, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque   +60 more
core   +1 more source

A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes [PDF]

open access: yes, 2014
Myristoylation is a lipid modification involving the addition of a 14-carbon unsaturated fatty acid, myristic acid, to the N-terminal glycine of a subset of proteins, a modification that promotes their binding to cell membranes for varied biological ...
Carlow, Clotilde K. S.   +7 more
core   +4 more sources

Moving nuclear receptor Nur77 to damaged mitochondria for clearance by mitophagy

open access: yesMolecular & Cellular Oncology, 2018
Selective clearance of damaged mitochondria can reverse pathological status in chronic inflammatory diseases. We recently identified a critical role of nuclear receptor Nur77 and celastrol in priming inflamed mitochondria for autophagy through its ...
Mengjie Hu   +4 more
doaj   +1 more source

Quality Control of Psoralea corylifolia L. Based on High-Speed Countercurrent Chromatographic Fingerprinting

open access: yesMolecules, 2020
Traditional Chinese medicine (TCM)has played an important role in promoting the health of Chinese people. The TCM Psoralea corylifolia L. has been used in the treatment of various kinds of diseases including enuresis, vitiligo, and calvities.
Xiaoxue Wu   +8 more
doaj   +1 more source

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

open access: yes, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W   +11 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

open access: yes, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada   +119 more
core   +1 more source

Home - About - Disclaimer - Privacy